Short Interest in Azitra, Inc. (NYSEAMERICAN:AZTR) Expands By 247.1%

Azitra, Inc. (NYSEAMERICAN:AZTR) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totalling 435,300 shares, an increase of 247.1% from the May 31st total of 125,400 shares. Based on an average daily trading volume, of 1,880,000 shares, the short-interest ratio is presently 0.2 days. Approximately 2.7% of the company’s shares are sold short.

Azitra Stock Performance

Shares of AZTR stock traded down $0.04 during trading hours on Friday, reaching $0.09. 3,365,822 shares of the stock traded hands, compared to its average volume of 3,520,313. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.80 and a current ratio of 2.80. Azitra has a 1-year low of $0.09 and a 1-year high of $4.33.

Azitra’s stock is set to reverse split before the market opens on Monday, July 1st. The 1-30 reverse split was announced on Monday, July 1st. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, July 1st.

Azitra (NYSEAMERICAN:AZTR) last released its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share (EPS) for the quarter. Azitra had a negative net margin of 1,644.90% and a negative return on equity of 237.52%.

Azitra Company Profile

Azitra, Inc, an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease.